Interactions between Hepatic Stellate Cells and the Immune System
The DOI matches its Crossref record.
Abstract
Stellate cells and immune cells are both active participants in the pathogenesis of liver disease. Interactions between these two populations are important determinants of disease outcome. Kupffer cells, neutrophils, and lymphocytes all have the potential to influence stellate cells. They produce a host of humoral mediators, including oxidants, nitric oxide, cytokines, eicosanoids, and proteinases, which can affect stellate cell proliferation, gene expression, and contractility. One important feature of stellate cell-immune cell interactions is that they are bidirectional. Not only do stellate cells receive signals from leukocytes, but they also elaborate signals that target leukocytes. Specifically, stellate cells can promote leukocyte chemotaxis and adherence, and they may also influence leukocyte activation by producing regulatory cytokines. Studies in culture provide an important background for understanding the effects of specific mediators on stellate cells and immune cells. Experiments in vivo offer an important adjunct, but often lead to confounding effects that limit interpretation. Both types of studies are required to develop a better understanding of the complex interplay between stellate cells and leukocytes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interplay between HSCs and hepatic immune cells, long recognized as a key feature of the hepatic injury response, has emerged as an especially important determinant of NASH pathogenesis (5, 7, 8).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [7]
Citations
Cites
Still being checked.
Cited by
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Liver: An organ with predominant innate immunity
Gao, B., Jeong, W.-I., & Tian, Z. (2008) · Hepatology · doi:10.1002/hep.22034 · Cited by 952
Pradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613
Apoptosis: The nexus of liver injury and fibrosis
Canbay, A., Friedman, S., & Gores, G. J. (2004) · Hepatology · doi:10.1002/hep.20051 · Cited by 527
Kupffer Cell Engulfment of Apoptotic Bodies Stimulates Death Ligand and Cytokine Expression
Canbay, A., Feldstein, A. E., Higuchi, H., Werneburg, N., Grambihler, A., Bronk, S. F., & Gores, G. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50472 · Cited by 470
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430
“These include (1) disruption of the normal ECM of the space of Disse as a consequence of hepatocyte damage and inflammatory infiltration[12,13]; (2) release of reactive oxygen species and other fibrogenic/proinflammatory mediators[14,15]; and (3) recruitment of immune cells, which in turn sustain HSC activation.[6,16]…”
BackgroundThe role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis
Elsharkawy, A. M., Oakley, F., & Mann, D. A. (2005) · Apoptosis · doi:10.1007/s10495-005-1055-4 · Cited by 419
Toll-Like Receptor Signaling in the Liver
Schwabe, R. F., Seki, E., & Brenner, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.038 · Cited by 401
Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences
Leclercq, I. A., Da Silva Morais, A., Schroyen, B., Van Hul, N., & Geerts, A. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.002 · Cited by 359
Tsukada, S., Parsons, C. J., & Rippe, R. A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.014 · Cited by 357
Friedman, S. L. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.013 · Cited by 350
Neutrophils Aggravate Acute Liver Injury During Obstructive Cholestasis in Bile Duct-Ligated Mice
Gujral, J. S., Farhood, A., Bajt, M. L., & Jaeschke, H. (2003) · Hepatology · doi:10.1053/jhep.2003.50341 · Cited by 342
Inhibition of T–Cell Responses by Hepatic Stellate Cells Via B7–H1-Mediated T–Cell Apoptosis in Mice
Yu, M., Chen, C., Liang, X., Wang, L., Gandhi, C. R., Fung, J. J., Lu, L., & Qian, S. (2004) · Hepatology · doi:10.1002/hep.20488 · Cited by 301
Hepatic Stellate Cells Secrete Angiopoietin 1 That Induces Angiogenesis in Liver Fibrosis
Taura, K., De Minicis, S., Seki, E., Hatano, E., Iwaisako, K., Osterreicher, C. H., Kodama, Y., Miura, K., Ikai, I., Uemoto, S., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.065 · Cited by 286
Zhan, S.-S., Jiang, J. X., Wu, J., Halsted, C., Friedman, S. L., Zern, M. A., & Torok, N. J. (2006) · Hepatology · doi:10.1002/hep.21093 · Cited by 284
Weiskirchen, R., & Tacke, F. (2014) · PubMed · doi:10.3978/j.issn.2304-3881.2014.11.03 · Cited by 256
Human Hepatic Stellate Cells Express CCR5 and RANTES to Induce Proliferation and Migration
Schwabe, R. F., Bataller, R., & Brenner, D. A. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00215.2003 · Cited by 252
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
“For instance, the pro-inflammatory cytokines TGF-α increases HSC proliferation, TGF-β inhibits HSC apoptosis and promotes ECM remodeling leading to a profibrogenic phenotype, TNF-α inhibits HSC apoptosis and induces chemokines and ICAM-1 in HSCs (Maher, 2001).”
BackgroundThe Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse
Canbay, A., Feldstein, A., Baskin-Bey, E., Bronk, S. F., & Gores, G. J. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060129 · Cited by 215
Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis
Canbay, A., Guicciardi, M. E., Higuchi, H., Feldstein, A., Bronk, S. F., Rydzewski, R., Taniai, M., & Gores, G. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17740 · Cited by 193
Cirrhosis: new research provides a basis for rational and targeted treatments
Iredale, J. P. (2003) · BMJ · doi:10.1136/bmj.327.7407.143 · Cited by 192
Liver fibrosis: mechanisms of immune-mediated liver injury
Xu, R., Zhang, Z., & Wang, F.-S. (2012) · Cellular & Molecular Immunology · doi:10.1038/cmi.2011.53 · Cited by 183
Böttcher, K., & Pinzani, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.016 · Cited by 182
CXC chemokine ligand 4 (Cxcl4) is a platelet‐derived mediator of experimental liver fibrosis†
Zaldivar, M. M., Pauels, K., von Hundelshausen, P., Berres, M., Schmitz, P., Bornemann, J., Kowalska, M. A., Gassler, N., Streetz, K. L., Weiskirchen, R., et al. (2010) · Hepatology · doi:10.1002/hep.23435 · Cited by 171
Hepatic Stellate Cells and Hepatocarcinogenesis
Barry, A. E., Baldeosingh, R., Lamm, R. J., Patel, K., Zhang, K., Dominguez, D. A., Kirton, K. J., Shah, A. P., & Dang, H. T. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00709 · Cited by 169
Apoptosis and angiogenesis: an evolving mechanism for fibrosis
Johnson, A., & DiPietro, L. A. (2013) · The FASEB Journal · doi:10.1096/fj.12-214189 · Cited by 160
Bonacchi, A., Petrai, I., DeFranco, R., Lazzeri, E., Annunziato, F., Efsen, E., Cosmi, L., Romagnani, P., Milani, S., Failli, P., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01194-6 · Cited by 160
Fatty Liver Disease: NASH and Related Disorders
(2004) · Wiley eBooks · doi:10.1002/9780470987438 · Cited by 154
Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment
McQuitty, C. E., Williams, R., Chokshi, S., & Urbani, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574276 · Cited by 146
“Initiation and perpetuation of HSC activation is modulated by complex cross-talk between liver cells, infiltrating immune cells and the ECM (18, 19).”
BackgroundMolecular basis of hepatic fibrosis
Hui, A. Y., & Friedman, S. L. (2003) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399403005684 · Cited by 118
Intraportal islet transplantation: the impact of the liver microenvironment
Delaune, V., Berney, T., Lacotte, S., & Toso, C. (2017) · Transplant International · doi:10.1111/tri.12919 · Cited by 127
Nuclear Factor-κB1 (p50) Limits the Inflammatory and Fibrogenic Responses to Chronic Injury
Oakley, F., Mann, J., Nailard, S., Smart, D. E., Mungalsingh, N., Constandinou, C., Ali, S., Wilson, S. J., Millward-Sadler, H., Iredale, J. P., et al. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62291-2 · Cited by 123
Modulation of hepatic stellate cells and reversibility of hepatic fibrosis
Huang, Y., Deng, X., & Liang, J. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.02.038 · Cited by 122
Fibrosis progression in chronic hepatitis C virus infection
McCaughan, G. W., & George, J. (2004) · Gut · doi:10.1136/gut.2003.026393 · Cited by 121
Thirunavukkarasu, C., Watkins, S. C., & Gandhi, C. R. (2006) · Hepatology · doi:10.1002/hep.21254 · Cited by 99
Starring stellate cells in liver immunology
Winau, F., Breunig, C., Darmoise, A., & Kaufmann, S. H. E. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.10.006 · Cited by 110
Lymphocyte traffic through sinusoidal endothelial cells is regulated by hepatocytes†
Edwards, S., Lalor, P. F., Nash, G. B., Rainger, G. E., & Adams, D. H. (2005) · Hepatology · doi:10.1002/hep.20585 · Cited by 96
The role of complement component 3 (C3) in differentiation of myeloid-derived suppressor cells
Hsieh, C., Chou, H.-S., Yang, H.-R., Lin, F., Bhatt, S., Qin, J., Wang, L., Fung, J. J., Qian, S., & Lü, L. (2013) · Blood · doi:10.1182/blood-2012-06-440214 · Cited by 100
Jiang, G., Yang, H.-R., Wang, L., Wildey, G. M., Fung, J., Qian, S., & Lu, L. (2008) · Transplantation · doi:10.1097/tp.0b013e31818bfd13 · Cited by 96
Oakley, F., Mann, J., Ruddell, R. G., Pickford, J., Weinmaster, G., & Mann, D. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211051200 · Cited by 88
Murine hepatic stellate cells veto CD8 T cell activation by a CD54-dependent mechanism
Schildberg, F. A., Wojtalla, A., Siegmund, S. V., Endl, E., Diehl, L., Abdullah, Z., Kurts, C., & Knolle, P. A. (2011) · Hepatology · doi:10.1002/hep.24352 · Cited by 90
“In general, HSCs actively shape local hepatic immune regulation through the release of soluble mediators with immune function and through the promotion of lymphocyte chemotaxis and adherence.(12) HSCs have potent innate immune functions(13) and, by executing these innate immune functions, promote hepatic fibrogenesis.”
Paschos, K. A., Majeed, A. W., & Bird, N. C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3719 · Cited by 89
Molecular Pathogenesis of Alcohol‐Induced Hepatic Fibrosis
Siegmund, S., & Brenner, D. A. (2005) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000189275.97419.58 · Cited by 88
Liver Involvement in the Histiocytic Disorders of Childhood
Jaffe, R. (2004) · Pediatric and Developmental Pathology · doi:10.1007/s10024-003-9876-z · Cited by 87
Liver inflammation during monocrotaline hepatotoxicity
Copple, B. L., Ganey, P. E., & Roth, R. A. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00164-1 · Cited by 84
Son, M. K., Ryu, Y.-L., Jung, K. H., Lee, H., Lee, H. S., YAN, H. H., Park, H. J., Ryu, J., Suh, J., Hong, S., et al. (2013) · Scientific Reports · doi:10.1038/srep03470 · Cited by 84
Benten, D., Kumaran, V., Joseph, B., Schattenberg, J., Popov, Y., Schuppan, D., & Gupta, S. (2005) · Hepatology · doi:10.1002/hep.20889 · Cited by 81
Xu, Y., Zhao, W., Xu, J., Li, J., Hong, Z., Yin, Z., & Wang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.6839 · Cited by 81
“com/oncotarget GM-CSF, and G-CSF have been implicated in MDSC development [6, 34-37].”
Molecular Mechanisms of Alcohol-Induced Hepatic Fibrosis
Siegmund, S. V., Dooley, S., & Brenner, D. A. (2005) · Digestive Diseases · doi:10.1159/000090174 · Cited by 75
Hepatic Stellate Cell-Immune Interactions in NASH
Carter, J. K., & Friedman, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.867940 · Cited by 79
“org 3 between HSC activation state and hepatic immune tone (7, 8, 27, 28).”
BackgroundReelin through the years: From brain development to inflammation
Alexander, A., Herz, J., & Calvier, L. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112669 · Cited by 78
Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis
Beljaars, L., Meijer, D. K. F., & Poelstra, K. (2002) · Frontiers in bioscience · doi:10.2741/a917 · Cited by 77
Role of hepatic stellate cell (HSC)-derived cytokines in hepatic inflammation and immunity
Gupta, G., Khadem, F., & Uzonna, J. E. (2019) · Cytokine · doi:10.1016/j.cyto.2018.09.004 · Cited by 69
Nitric oxide augments mesenchymal stem cell ability to repair liver fibrosis
Ali, G., Mohsin, S., Khan, M., Nasir, G. A., Shams, S., Khan, S. N., & Riazuddin, S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-75 · Cited by 70
Cheng, S., Zou, Y., Zhang, M., Bai, S., Tao, K., Wu, J., Shi, Y., Wu, Y., Lu, Y., He, K., et al. (2023) · MedComm · doi:10.1002/mco2.378 · Cited by 49
Yang, M.-C., Wang, C., Liao, P., Yen, C., & Shan, Y. (2014) · Europe PMC (PubMed Central) · Cited by 72
Xuemin, W., Tang, X., Gong, X., Albanis, E., Friedman, S. L., & Mao, Z. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.007 · Cited by 69
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats
Leclercq, I. A. (2006) · Gut · doi:10.1136/gut.2005.079194 · Cited by 67
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Lambrecht, J., van Grunsven, L. A., & Tacke, F. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1774553 · Cited by 64
Olaso, E., Arteta, B., Benedicto, A., Crende, O., & Friedman, S. L. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.002 · Cited by 66
Emerging Therapies for Liver Fibrosis
Fowell, A. J., & Iredale, J. P. (2006) · Digestive Diseases · doi:10.1159/000090320 · Cited by 64
Martinelli, A. L. C., Ramalho, L. N. Z., & Zucoloto, S. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03255.x · Cited by 64
Thirunavukkarasu, C., Uemura, T., Wang, L. F., Watkins, S. C., & Gandhi, C. R. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20366 · Cited by 62
Recent advances in the pathogenesis and diagnosis of liver fibrosis
Torok, N. J. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2181-x · Cited by 61
Richardson, M. M., Powell, E. E., Barrie, H. D., Clouston, A. D., Purdie, D., & Jonsson, J. R. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.032557 · Cited by 59
Activated Hepatic Stellate Cells Mediate the Differentiation of Macrophages
Chang, J., Hisamatsu, T., Shimamura, K., Yoneno, K., Adachi, M., Naruse, H., Igarashi, T., Higuchi, H., Matsuoka, K., Kitazume, M. T., et al. (2013) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01111.x · Cited by 56
Adrian, J. E., Poelstra, K., Scherphof, G. L., Meijer, D. K. F., van Loenen-Weemaes, A. M., Reker‐Smit, C., Morselt, H. W. M., Zwiers, P. J., & Kamps, J. A. A. M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.117945 · Cited by 56
Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone
Nagler, A., Ohana, M., Shibolet, O., Shapira, M. Y., Alper, R., Vlodavsky, I., Pines, M., & Ilan, Y. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.036 · Cited by 53
Infiltrating neutrophils in bile duct-ligated livers do not promote hepatic fibrosis
Saito, J. M., Bostick, M. K., Campe, C. B., Xu, J., & Maher, J. J. (2003) · Hepatology Research · doi:10.1016/s1386-6346(02)00247-4 · Cited by 51
Self-citationTao, L., Cheng, Y., Ding, D., Mei, S., Xu, J., Yu, J., Ouyang, Q., Deng, L., Chen, Q., Li, Q., et al. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0700-y · Cited by 46
Suflețel, R. T., Melincovici, C. S., Gheban, B., Zaharie, T., & Mihu, C. M. (2021) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.61.3.01 · Cited by 46
Peroxynitrite‐mediated matrix metalloproteinase‐2 activation in human hepatic stellate cells
Migita, K., Maeda, Y., Abiru, S., Komori, A., Yokoyama, T., Takii, Y., Nakamura, M., Yatsuhashi, H., Eguchi, K., & Ishibashi, H. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.04.071 · Cited by 46
Greupink, R., Bakker, H. I., Reker‐Smit, C., van Loenen-Weemaes, A. M., Kok, R. J., Meijer, D. K. F., Beljaars, L., & Poelstra, K. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.04.014 · Cited by 44
Chu, D., Luo, Q., Li, C., Gao, Y., Yu, L., Wei, W., Wu, Q., & Shen, J. (2007) · Parasitology · doi:10.1017/s0031182007002946 · Cited by 42
Cummins, C. B., Wang, X., Nunez Lopez, O., Graham, G., Tie, H.-Y., Zhou, J., & Radhakrishnan, R. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061567 · Cited by 40
Anselmi, K., Stolz, D. B., Nalesnik, M. A., Watkins, S. C., Kamath, R., & Gandhi, C. R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.024 · Cited by 40
Lopez, O. N., Bohanon, F. J., Wang, X., Ye, N., Corsello, T., Rojas-Khalil, Y., Chen, H., Chen, H., Zhou, J., & Radhakrishnan, R. S. (2016) · RSC Advances · doi:10.1039/c6ra17459k · Cited by 39
Targeted delivery of drugs for liver fibrosis
Li, F., & Wang, J. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902936834 · Cited by 38
Xu, Y., Huang, Y., Xu, W., Zheng, X., Yi, X., Huang, L., Wang, Y., & Wu, K. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s234920 · Cited by 37
Deng, J., Zeng, X., Li, J., Luo, L., Yang, Y., & Luan, T. (2023) · Science of The Total Environment · doi:10.1016/j.scitotenv.2023.164082 · Cited by 36
Dasuri, K., Nguyen, A., Zhang, L., Fernandez-Kim, O. S., Bruce-Keller, A. J., Blalock, B. A., Cabo, R. D., & Keller, J. N. (2009) · Free Radical Research · doi:10.1080/10715760802534812 · Cited by 37
Roy, D. N., Sen, G., Chowdhury, K. D., & Biswas, T. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.09.027 · Cited by 36
RetractedZhang, M., Hu, X., Li, S., Chen, L., Li, J., Zong, Y., Qi, W., & Yang, H. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2017.04.008 · Cited by 36
Hintermann, E., Ehser, J., Bayer, M., Pfeilschifter, J. M., & Christen, U. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.05.001 · Cited by 35
Angiotensin II: a key mediator in the development of liver fibrosis and cancer
Saber, S. (2018) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-018-0020-7 · Cited by 35
Liver-related effects of chronic hepatitis C antiviral treatment
Laursen, T. L., Sandahl, T. D., Kazankov, K., George, J., & Grønbæk, H. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i22.2931 · Cited by 35
Al‐Dhamin, Z., Liu, L., Li, D., Zhang, S., Dong, S., & Nan, Y. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i47.7444 · Cited by 35
Zhou, L., Li, Y., Liang, Q., Liu, J., & Liu, Y. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2044485 · Cited by 34
Bian, E., Zhao, B., Huang, C. Z., Wang, H., Meng, X., Wu, B., Ma, T., Zhang, L., Lv, X., & Li, J. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.017 · Cited by 34
Epigenetic regulation of hepatic stellate cell activation
Mann, D. A., & Mann, J. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05295.x · Cited by 34
Hepatic Stellate Cell Activation and Hepatic Fibrosis Induced by Ischemia/Reperfusion Injury
Cheng, F., Li, Y., Feng, L., & Li, S. (2008) · Transplantation Proceedings · doi:10.1016/j.transproceed.2008.06.052 · Cited by 33
Greupink, R., Bakker, H. I., van Goor, H., de Borst, M. H., Beljaars, L., & Poelstra, K. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9025-2 · Cited by 33
Interorgan communication with the liver: novel mechanisms and therapeutic targets
Zhao, J., Zhang, X., Li, Y., Yu, J., Chen, Z., Niu, Y., Ran, S., Wang, S., Ye, W., Luo, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1314123 · Cited by 32
Pathogenesis of liver damage in HCV-HIV patients.
Bruno, R., Sacchi, P., Puoti, M., Maiocchi, L., Patruno, S. F. A., Cima, S., & Filice, G. (2008) · PubMed · Cited by 30
Xia, Y., Chen, R., Ye, S., Sun, R., Chen, J., & Zhao, Y. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9399-3 · Cited by 29
Receptor-Mediated Hepatic Uptake of M6P−BSA-Conjugated Triplex-Forming Oligonucleotides in Rats
Ye, Z., Cheng, K., Guntaka, R. V., & Mahato, R. I. (2006) · Bioconjugate Chemistry · doi:10.1021/bc060006z · Cited by 29
Reynaert, H., Rombouts, K., Jia, Y., Urbain, D., Chatterjee, N., Uyama, N., & Geerts, A. E. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706298 · Cited by 28
Bioconjugation of Oligonucleotides for Treating Liver Fibrosis
Ye, Z., Houssein, H. S. H., & Mahato, R. I. (2007) · Oligonucleotides · doi:10.1089/oli.2007.0097 · Cited by 28
Metadata
- Authors
- Maher, J. J.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Maher, Jacquelyn J.
- ORCID
- Maher, Jacquelyn J.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2001
- Volume
- 21
- Issue
- 03
- Pages
- 417-426
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2087877540
- Cited by
- 198
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 7 · 2020: 10 · 2018: 6 · 2017: 8 · 2016: 6 · 2015: 7 · 2014: 8 · 2013: 13 · 2012: 10
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k02aa000215-04, 5r01aa007810-12)
- National Institute on Alcohol Abuse and Alcoholism (AA07810, AA-00215)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK026743)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- hepatic stellate cells, Kupffer cells, neutrophils, lymphocytes, cytokines, nitric oxide, eicosanoids, proteolytic enzymes, stellate cell proliferation, leukocyte chemotaxis, leukocyte activation, liver disease pathogenesis
- MeSH terms
- Cell Adhesion, Cell Communication, Chemotaxis, Humans, Immune System, Kupffer Cells, Leukocytes, Liver, Liver Cirrhosis, Neutrophils, Signal Transduction, Cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.